Early use of β blockers reduced 30 day mortality to 2.3% compared to 8.6% in non-users, with an adjusted hazard ratio of 0.46 (95% CI 0.26 to 0.82).
Cohort (n=2,679)
Yes
Does beta-blocker therapy reduce short-term and long-term mortality in patients with acute myocardial infarction without heart failure or left ventricular dysfunction?
Early beta-blocker use post-myocardial infarction improves 30-day survival, but prolonged use beyond one year in patients without heart failure or left ventricular dysfunction does not confer a 5-year mortality benefit.
Effect estimate: HR 0.46 (95% CI 0.26 to 0.82)
Absolute Event Rate: 2.3% vs 8.6%
p-value: p=0.008
Early β blocker use was associated with reduced 30 day mortality in patients with acute myocardial infarction, and discontinuation of β blockers at one year was not associated with higher five year mortality. These findings question the utility of prolonged β blocker treatment after acute myocardial infarction in patients without heart failure or left ventricular dysfunction.Trial registration Clinical trials NCT00673036.
Puymirat et al. (2016) conducted a cohort in acute myocardial infarction without heart failure (n=2,679). β blockers vs. No β blockers was evaluated on 30 day mortality (HR 0.46, 95% CI 0.26 to 0.82, p=0.008). Early use of β blockers reduced 30 day mortality to 2.3% compared to 8.6% in non-users, with an adjusted hazard ratio of 0.46 (95% CI 0.26 to 0.82).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: